Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02922426 · ClinicalTrials.gov registry record · Phase 1

An Insulin Sensitivity Study in Healthy Subjects

A Phase 1 study of Healthy Volunteers, sponsored by Alkermes.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT02922426 is a Phase 1 study of Healthy Volunteers that has completed, run by Alkermes. The registered enrollment target is 60 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02922426, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Alkermes.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Olanzapine
  • DRUG ALKS 3831

Study Locations (1)

California

  • Alkermes Investigational Site - Chula Vista

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2016-09
Est. Completion 2017-07-20
Phase Phase 1

Sponsor

Alkermes

66 total trials

What the Registry Record Tells You About NCT02922426

The ClinicalTrials.gov registry entry for NCT02922426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (88% lower). The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02922426 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT02922426 about?

NCT02922426 is a clinical study titled "An Insulin Sensitivity Study in Healthy Subjects". This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.

What is the current status of trial NCT02922426?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-09. Estimated completion is 2017-07-20.

What conditions does trial NCT02922426 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT02922426?

The interventions under investigation include: Placebo (DRUG), Olanzapine (DRUG), ALKS 3831 (DRUG).

Who is sponsoring clinical trial NCT02922426?

This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02922426 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.